Beth King: What Makes Stago Different From Every Other Vendor in Hemostasis?
Beth King, Portfolio Partnership Executive at Stago, shared a post on LinkedIn:
”What makes Stago different from every other vendor in hemostasis?
1. Hemostasis is all we do.
It isn’t one part of a larger diagnostics portfolio—it is our focus. We take coagulation seriously, and that commitment shows in our instrumentation, reagents, service, support, and expertise.
2. Our people make the difference.
From our sales team and applications specialists to our service engineers and leadership, we are dedicated to our customers and their laboratories. Many of us come from the laboratory ourselves, so we understand the challenges laboratorians face every day.
3. We make coagulation simpler.
Our goal is to help laboratories work efficiently, confidently, and accurately—without unnecessary complexity.
4. Our technology truly sets us apart.
Stago’s mechanical, viscosity-based clot detection is not dependent on optical clot detection. That means hemolysis, icterus, and lipemia do not create the same interference challenges associated with photometric systems.
Your staff should not have to spend valuable time interpreting questionable clot curves or wondering whether the appearance of a sample is preventing them from obtaining the critical coagulation result a patient needs.
That is the Stago Difference.
We are Stago 3.0.
Make it simple.
Make it Stago.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question